CStone Pharmaceuticals
HKEX:2616

Watchlist Manager
CStone Pharmaceuticals Logo
CStone Pharmaceuticals
HKEX:2616
Watchlist
Price: 6.12 HKD 6.43% Market Closed
Market Cap: 9B HKD

CStone Pharmaceuticals
Total Current Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

CStone Pharmaceuticals
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
CStone Pharmaceuticals
HKEX:2616
Total Current Liabilities
¥625.8m
CAGR 3-Years
-11%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Current Liabilities
¥16B
CAGR 3-Years
16%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Total Current Liabilities
¥5B
CAGR 3-Years
13%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Total Current Liabilities
¥1.7B
CAGR 3-Years
37%
CAGR 5-Years
70%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Current Liabilities
¥2B
CAGR 3-Years
-5%
CAGR 5-Years
33%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Total Current Liabilities
¥1.1B
CAGR 3-Years
-31%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

CStone Pharmaceuticals
Glance View

Market Cap
8.4B HKD
Industry
Biotechnology

Cstone Pharmaceuticals Co. Ltd. engages in the research and development of highly complex biopharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 264 full-time employees. The company went IPO on 2019-02-26. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The firm conducts its businesses mainly in domestic market.

Intrinsic Value
2.08 HKD
Overvaluation 66%
Intrinsic Value
Price

See Also

What is CStone Pharmaceuticals's Total Current Liabilities?
Total Current Liabilities
625.8m CNY

Based on the financial report for Jun 30, 2025, CStone Pharmaceuticals's Total Current Liabilities amounts to 625.8m CNY.

What is CStone Pharmaceuticals's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
13%

Over the last year, the Total Current Liabilities growth was -12%. The average annual Total Current Liabilities growth rates for CStone Pharmaceuticals have been -11% over the past three years , 13% over the past five years .

Back to Top